Sale!

CEBPA Gene Leukemia Myeloid Acute Form Due to CEBPA Germline Mutation Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The CEBPA gene plays a critical role in the development and function of various types of cells, including those in the blood-forming system. Mutations in this gene can lead to acute myeloid leukemia (AML), a rapid-growing cancer of the blood and bone marrow. Specifically, germline mutations in the CEBPA gene are associated with a familial predisposition to AML, making individuals with such mutations at a higher risk of developing this form of leukemia.

To identify the presence of germline mutations in the CEBPA gene, a specialized genetic test is conducted. This test is crucial for individuals with a family history of AML or those who have been diagnosed with the disease, as it helps in determining the genetic underpinnings of the condition. Understanding whether the leukemia is caused by a CEBPA germline mutation can significantly impact treatment decisions and risk assessments for family members.

In the United Arab Emirates, DNA Labs UAE offers this important genetic test. The cost of the test is set at 4400 AED. The test involves analyzing the patient’s DNA, extracted from a blood sample, to look for mutations in the CEBPA gene. Results from this test can provide valuable insights into the patient’s condition, enabling personalized treatment plans and informing family members about their potential risk, guiding them in taking preventive measures or considering their own genetic testing.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CEBPA Gene Leukemia Myeloid Acute Form Genetic Test

At DNA Labs UAE, we offer a comprehensive genetic test for the CEBPA gene associated with myeloid acute form of acute myeloid leukemia (AML). This test can detect CEBPA germline mutations that may be present in individuals and their family members. Our test provides valuable information for diagnosis, prognosis, and treatment decisions.

Test Details

The CEBPA gene is a transcription factor that plays a crucial role in the development and differentiation of myeloid cells. Mutations in the CEBPA gene have been linked to the development of AML, particularly the myeloid acute form.

Our genetic test utilizes Next-Generation Sequencing (NGS) technology, which allows for the analysis of multiple genes simultaneously. By analyzing the CEBPA gene, we can identify any genetic variations or mutations that may be present.

Symptoms and Diagnosis

Individuals with CEBPA germline mutations may have an increased risk of developing AML. Common symptoms of AML include fatigue, shortness of breath, easy bruising or bleeding, and frequent infections. Diagnosis of AML typically involves a combination of physical examinations, blood tests, and bone marrow biopsies.

Test Components and Price

Our CEBPA Gene Leukemia Myeloid Acute Form Genetic Test is priced at AED 4400.0. The test requires a blood sample or extracted DNA. Alternatively, one drop of blood can be collected on an FTA card for testing.

Report Delivery and Test Department

After sample collection, the report will be delivered within 3 to 4 weeks. Our test is conducted in the Genetics department by experienced professionals.

Genetic Counseling and Pre-Test Information

Prior to undergoing the CEBPA Gene Leukemia Myeloid Acute Form Genetic Test, a genetic counseling session is recommended. This session helps in drawing a pedigree chart of family members affected by CEBPA germline mutations. Our team of genetic counselors can provide guidance and support throughout the testing process.

Benefits of Genetic Testing

If a CEBPA germline mutation is identified through our NGS genetic test, it can provide valuable information for both the individual and their healthcare team. The results can help guide treatment decisions, determine prognosis, and potentially identify family members who may also be at risk of developing AML due to the same genetic mutation.

It is important to note that genetic testing should be performed and interpreted by healthcare professionals with expertise in genetics, such as genetic counselors or medical geneticists, to ensure accurate and appropriate interpretation of the results.

At DNA Labs UAE, we are committed to providing reliable and accurate genetic testing services. Contact us today to learn more about our CEBPA Gene Leukemia Myeloid Acute Form Genetic Test and schedule a consultation with our oncologist.

Test Name CEBPA Gene Leukemia myeloid acute form due to CEBPA germline mutation Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Cancer
Doctor Oncologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CEBPA Gene Leukemia, myeloid acute form, due to CEBPA germline mutation NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CEBPA Gene Leukemia, myeloid acute form, due to CEBPA germline mutation NGS Genetic DNA Test gene CEBPA
Test Details

The CEBPA gene is a transcription factor that plays a crucial role in the development and differentiation of myeloid cells. Mutations in the CEBPA gene have been associated with the development of acute myeloid leukemia (AML), particularly the myeloid acute form.

NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously and identify any genetic variations or mutations that may be present. In the context of AML, NGS genetic testing can be used to detect CEBPA germline mutations, which are inherited mutations present in the DNA of all cells in the body.

CEBPA germline mutations are relatively rare and are associated with a distinct subtype of AML characterized by a better prognosis compared to other forms of AML. Individuals with CEBPA germline mutations may have an increased risk of developing AML, and genetic testing can help identify individuals who may benefit from closer monitoring or early intervention.

If a CEBPA germline mutation is identified through NGS genetic testing, it can provide valuable information for both the individual and their healthcare team. It can help guide treatment decisions, determine prognosis, and potentially identify family members who may also be at risk of developing AML due to the same genetic mutation.

It is important to note that genetic testing should be performed and interpreted by healthcare professionals with expertise in genetics, such as genetic counselors or medical geneticists, to ensure accurate and appropriate interpretation of the results.